Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

02. Dezember 2025 07:09 ET | Quelle: Nkarta, Inc.

Nkarta to Participate in Evercore Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
10. November 2025 16:01 ET | Quelle: Nkarta, Inc.

Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights

Enrollment now underway in second dose-escalation cohort Deep B-cell depletion observed in all patients treated to date who received NKX019 with lymphodepletion using fludarabine and cyclophosphamide...
30. Oktober 2025 13:14 ET | Quelle: Nkarta, Inc.

Nkarta to Participate in November Investor Conferences

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today...
22. Oktober 2025 10:07 ET | Quelle: Nkarta, Inc.

Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
02. September 2025 08:01 ET | Quelle: Nkarta, Inc.

Nkarta to Participate in a September Investor Conference

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies,...
12. August 2025 16:01 ET | Quelle: Nkarta, Inc.

Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights

Initial update for NKX019 in multiple autoimmune indications expected in second half of 2025Cash balance of $334.0 million on June 30, 2025, including cash, cash equivalents and investments, expected...
23. Juli 2025 08:01 ET | Quelle: Nkarta, Inc.

Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series

SOUTH SAN FRANCISCO, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today...
06. Juni 2025 08:52 ET | Quelle: Nkarta, Inc.

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
14. Mai 2025 16:01 ET | Quelle: Nkarta, Inc.

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1...
01. April 2025 08:01 ET | Quelle: Nkarta, Inc.

Nkarta to Participate in an April Investor Conference

SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its...

Nächste Seite